Apart from making significant cost reductions, Regeneus is in discussions with potential partners about licensing, development and distribution of its allogeneic stem cell products CryoShot and Progenza.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor